NASDAQ:CDXS - Codexis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.90 +0.15 (+0.95 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$15.90
Today's Range$15.70 - $16.60
52-Week Range$4.80 - $16.80
Volume299,356 shs
Average Volume376,158 shs
Market Capitalization$838.54 million
P/E Ratio-31.80
Dividend YieldN/A
Beta-1.68
Codexis logoCodexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorIndustrial Products
SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100

Debt

Debt-to-Equity Ratio0.02
Current Ratio1.67
Quick Ratio1.61

Price-To-Earnings

Trailing P/E Ratio-31.80
Forward P/E Ratio-58.89
P/E GrowthN/A

Sales & Book Value

Annual Sales$50.02 million
Price / Sales16.92
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book31.18

Profitability

EPS (Most Recent Fiscal Year)($0.50)
Net Income$-22,990,000.00
Net Margins-36.06%
Return on Equity-87.65%
Return on Assets-42.15%

Miscellaneous

Employees116
Outstanding Shares53,240,000
Market Cap$838.54

Codexis (NASDAQ:CDXS) Frequently Asked Questions

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $14.04 million during the quarter, compared to analysts' expectations of $13.50 million. Codexis had a negative net margin of 36.06% and a negative return on equity of 87.65%. View Codexis' Earnings History.

What price target have analysts set for CDXS?

4 analysts have issued 12-month price targets for Codexis' stock. Their predictions range from $11.00 to $18.00. On average, they expect Codexis' share price to reach $14.25 in the next twelve months. This suggests that the stock has a possible downside of 10.4%. View Analyst Ratings for Codexis.

What is the consensus analysts' recommendation for Codexis?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Codexis' key competitors?

Who are Codexis' key executives?

Codexis' management team includes the folowing people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 54)
  • Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 65)
  • Mr. Michael D. A. Aldridge, Sr. VP of Corp. & Strategic Devel. (Age 51)
  • Dr. James J. Lalonde, Sr. VP of R&D (Age 57)
  • Mr. Achilles Antonio Clement, Director of Latin America

Has Codexis been receiving favorable news coverage?

News stories about CDXS stock have trended positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Codexis earned a media sentiment score of 0.26 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 44.75 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.97%), Comprehensive Portfolio Management LLC (0.11%) and Campbell & CO Investment Adviser LLC (0.02%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

Which institutional investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Insider Buying and Selling for Codexis.

Which institutional investors are buying Codexis stock?

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co. and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Codexis.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $15.90.

How big of a company is Codexis?

Codexis has a market capitalization of $838.54 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]


MarketBeat Community Rating for Codexis (NASDAQ CDXS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.